XpresCheck™ COVID-19 Testing Facility Opens at Denver International Airport Today
December 16 2020 - 8:30AM
XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”),
a health and wellness company, in conjunction with Denver
International Airport (DEN), announces the opening of an
XpresCheck™ COVID-19 testing facility at Denver International
Airport today.
This XpresCheck is a pop-up facility in the
center of Concourse B, post-security. The facility has six separate
testing rooms with an anticipated capacity to administer over 400
tests per day.
COVID-19 testing options will include the Rapid
Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR)
Test. These services will be available to all airline passengers as
well as all airport employees, including airline employees,
contractors and workers, concessionaires and their employees, TSA
officers, and U.S. Customs and Border Protection (CPB) agents. All
insurance plans are accepted outside of network and all information
will remain private and HIPAA-compliant.
"The XpresCheck opening at Denver International
Airport marks our fifth COVID-19 testing facility and first pop-up
location,” said Doug Satzman, XpresSpa CEO. “Given the spike in
cases across the country, it is more important than ever that there
is reliable COVID-19 testing for airport employees and the
traveling public and we therefore look forward to providing this
important service to customers. Our new pop-up building methodology
will also enable us to accelerate XpresCheck’s rollout to
additional airports at a lower cost than our original modular
constructed facilities.”
“We are excited to welcome XpresCheck to Denver
and the opportunity for COVID-19 testing at the airport,” said DEN
CEO Kim Day. “The health and safety of our passengers has been, and
remains, our top priority and further testing opportunities
furthers our efforts to provide a safe passenger experience.”
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading
global health and wellness holding company. XpresSpa Group’s core
asset, XpresSpa, is a leading airport retailer of spa services and
related health and wellness products, with 50 locations in 25
airports globally. Through its XpresTest, Inc. subsidiary, the
Company also provides COVID-19 screening and testing under its
XpresCheck™ brand at JFK International Airport, Newark Liberty
International Airport, Logan International Airport, Sky Harbor
International Airport, and Denver International Airport. To learn
more about XpresSpa Group, visit: www.XpresSpaGroup.com. To learn
more about XpresSpa, visit www.XpresSpa.com. To learn more about
XpresCheck, visit www.XpresCheck.com.
About Denver International
Airport
Denver International Airport is the
fifth-busiest airport in the United States, with more than 69
million passengers traveling through the airport in 2019. DEN is
the primary economic engine for the state of Colorado, generating
more than $33 billion for the region annually. For more
information, visit www.FlyDenver.com.
Forward-Looking StatementsThis
press release may contain "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. These include
statements preceded by, followed by or that otherwise include the
words "believes," "expects," "anticipates," "estimates,"
"projects," "intends," "should," "seeks," "future," "continue," or
the negative of such terms, or other comparable terminology. In
particular, these statements include, without limitation,
statements about our expectations relating to our new XpresCheck™
concept, being able to expand testing to other communicable
diseases as well as administer vaccinations for the seasonal flu,
our positioning to be part of the national rollout of a COVID-19
vaccination when it becomes available (including whether such
vaccination becomes available in the near term or at all), the
degree to which our public testing model assists passengers meet
testing requirements in select states and countries, our ability to
identify and gain access to the latest and best COVID-19 testing
methodologies and equipment, and our ability further expand our
initial sites, and our overall ability to manage the regulatory
challenges associated with this business line. Forward-looking
statements relating to expectations about future results or events
are based upon information available to XpresSpa Group as of
today's date and are not guarantees of the future performance of
the company, and actual results may vary materially from the
results and expectations discussed. Additional information
concerning these and other risks is contained in XpresSpa Group’s
most recently filed Annual Report on Form 10-K, Quarterly Report on
Form 10-Q, recent Current Reports on Form 8-K and other Securities
and Exchange Commission filings. All subsequent written and oral
forward-looking statements concerning XpresSpa Group, or other
matters and attributable to XpresSpa Group or any person acting on
its behalf are expressly qualified in their entirety by the
cautionary statements above. XpresSpa Group does not undertake any
obligation to publicly update any of these forward-looking
statements to reflect events or circumstances that may arise after
the date hereof.
Investor Relations:ICRRaphael
Grossir@xpresspagroup.com(203) 682-8253
MediaJulie
FergusonJulie@jfprmedia.com(312) 385-0098
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Sep 2023 to Sep 2024